CORMEDIX INC (CRMD) Stock Price & Overview
NASDAQ:CRMD • US21900C3088
Current stock price
The current stock price of CRMD is 6.57 USD. Today CRMD is down by -2.09%. In the past month the price decreased by -8.88%. In the past year, price increased by 12.12%.
CRMD Key Statistics
- Market Cap
- 519.359M
- P/E
- 3.25
- Fwd P/E
- 4.83
- EPS (TTM)
- 2.02
- Dividend Yield
- N/A
CRMD Stock Performance
CRMD Stock Chart
CRMD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD is a bad performer in the overall market: 82.94% of all stocks are doing better.
CRMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CRMD. CRMD has an average financial health and profitability rating.
CRMD Earnings
On March 5, 2026 CRMD reported an EPS of 0.18 and a revenue of 128.62M. The company missed EPS expectations (-78.38% surprise) and missed revenue expectations (-0.73% surprise).
CRMD Forecast & Estimates
13 analysts have analysed CRMD and the average price target is 14.86 USD. This implies a price increase of 126.22% is expected in the next year compared to the current price of 6.57.
For the next year, analysts expect an EPS growth of -32.63% and a revenue growth -1.16% for CRMD
CRMD Groups
Sector & Classification
CRMD Financial Highlights
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 2.02. The EPS increased by 712.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 52.31% | ||
| ROA | 19.74% | ||
| ROE | 40.23% | ||
| Debt/Equity | 0.36 |
CRMD Ownership
CRMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.36 | 836.411B | ||
| JNJ | JOHNSON & JOHNSON | 20.82 | 584.064B | ||
| MRK | MERCK & CO. INC. | 22.82 | 291.989B | ||
| PFE | PFIZER INC | 9.3 | 157.966B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 121.638B | ||
| ZTS | ZOETIS INC | 16.44 | 49.106B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.97 | 26.749B | ||
| VTRS | VIATRIS INC | 5.17 | 14.922B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.28 | 11.654B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.21B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.616B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.596B | ||
| CORT | CORCEPT THERAPEUTICS INC | 46.14 | 4.055B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRMD
Company Profile
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Company Info
IPO: 2010-03-25
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 65
Phone: 13026365400
CORMEDIX INC / CRMD FAQ
What does CRMD do?
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
What is the current price of CRMD stock?
The current stock price of CRMD is 6.57 USD. The price decreased by -2.09% in the last trading session.
What is the dividend status of CORMEDIX INC?
CRMD does not pay a dividend.
What is the ChartMill rating of CORMEDIX INC stock?
CRMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for CORMEDIX INC?
CORMEDIX INC (CRMD) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for CORMEDIX INC?
The Revenue of CORMEDIX INC (CRMD) is expected to decline by -1.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for CRMD stock?
You can find the ownership structure of CORMEDIX INC (CRMD) on the Ownership tab.